Takeda Pharmaceutical (NYSE:TAK) Insider Sells $531,519.30 in Stock

Key Points

• Takeda insider Giles Richard Platford sold 31,083 shares at an average price of $17.10, generating $531,519.30. The sale covered tax-withholding obligations tied to vested equity awards and reduced his ownership by 8.96%.
• Takeda shares recently traded at $17.42, with a market capitalization of approximately $55.82 billion. The company reported quarterly earnings of $0.56 per share on $6.90 billion in revenue.
• Analyst sentiment is mixed, with two Buy ratings, one Hold and one Sell; MarketBeat’s consensus rating is Hold. Institutional investors own 9.17% of the company, with several major funds increasing their positions.

Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Giles Richard Platford sold 31,083 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30. Following the transaction, the insider directly owned 315,838 shares of the company's stock, valued at $5,400,829.80. The trade was a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Shares of TAK stock traded down $0.06 during trading hours on Wednesday, hitting $17.42. The company had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm's fifty day moving average is $16.49 and its 200 day moving average is $17.13. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The firm has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. On average, sell-side analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Weiss Ratings cut Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, July 30th. Wall Street Zen upgraded Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of "Hold".

Institutional Trading of Takeda Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership lifted its stake in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company's stock valued at $88,596,000 after purchasing an additional 2,854,069 shares during the period. UBS Group AG increased its holdings in Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company's stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd lifted its stake in Takeda Pharmaceutical by 407.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company's stock valued at $25,998,000 after buying an additional 1,426,184 shares during the period. Van ECK Associates Corp lifted its stake in Takeda Pharmaceutical by 98.4% in the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company's stock valued at $35,941,000 after buying an additional 1,143,117 shares during the period. Finally, Voloridge Investment Management LLC boosted its holdings in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company's stock worth $15,005,000 after buying an additional 880,289 shares during the last quarter. Institutional investors own 9.17% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source